TCR , Inc. is a discovery stage pharmaceutical company focused on engineering T cells for cancer therapy. The company's vast expertise in T cell engagement and a deep understanding of T cell receptor biology enabled the creation of a novel first-in-class approach that is highly differentiated from CAR-T cells and from T cells engineered to express defined TCR alpha/beta chains. TCR was founded by MPM Capital and has scientific operations in Kendall Square, Cambridge, Massachusetts to leverage best-in-class technologies and nucleate top-tier academic laboratories around the world.
Cambridge, US
Size (employees)
34 (est)+18%
TCR2 Therapeutics was founded in 2015 and is headquartered in Cambridge, US
Report incorrect company information

TCR2 Therapeutics Office Locations

TCR2 Therapeutics has an office in Cambridge
Cambridge, US (HQ)
675 W Kendall St
Show all (1)
Report incorrect company information

TCR2 Therapeutics Financials and Metrics

Summary Metrics

Founding Date


Total Funding

$173.3 m

Latest funding size

$125 m

Time since last funding

3 months ago


TCR2 Therapeutics's latest funding round in March 2018 was reported to be $125 m. In total, TCR2 Therapeutics has raised $173.3 m
Show all financial metrics
Report incorrect company information